Evidence map›Paper›PMID 25934441›Full record

ArticleThe Journal of urology2015

A Murine Model of K-RAS and β-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor.

Yajun Yi, Dina Polosukhina, Harold D Love, Austin Hembd, Michael Pickup, Harold L Moses, Harold N Lovvorn, Roy Zent, Peter E Clark

Open access · greenAbstract read
In one paragraph

Article in The Journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. The Vanderbilt O'Brien Kidney Center.American journal of physiology. Renal physiology · 2021
    Review
  4. Claudin-2 inhibits renal clear cell carcinoma progression by inhibiting YAP-activation.Journal of experimental & clinical cancer research : CR · 2021
    Article
  5. FXR1 expression domain in Wilms tumor.Journal of pediatric surgery · 2019
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yajun YiDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Dina PolosukhinaDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Harold D LoveDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Austin HembdDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Michael PickupDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Harold L MosesDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Harold N LovvornDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Roy ZentDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
Peter E ClarkDepartment of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: peter.clark@vanderbilt.edu.
Vanderbilt University Medical Center · US

Funding

The Laminin Receptors in Kidney FibrosisR01DK069921 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROY ZENT · 2005 to 2026
$9.5M
Vanderbilt O'Brien Mouse Kidney Physiology and Disease CenterP30DK079341 · NIDDK · VANDERBILT UNIVERSITY · PI HARRIS, RAYMOND C. · 2008 to 2013
$4.4M
Vanderbilt Student Research Training ProgramT35DK007383 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI William Heerman · 1986 to 2026
$4.1M
TRAIL Mediated Apoptosis in Renal Cell CarcinomaK08CA113452 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CLARK, PETER E · 2005 to 2009
$693k
The ILK/PINCH/Parvin complex in renal tubulogenesisI01BX002196 · VA · VETERANS HEALTH ADMINISTRATION · PI ZENT, ROY · 2013 to 2025
–
BLRD VA I01 BX002196NCI NIH HHS K08 CA113452NIDDK NIH HHS P30 DK079341NIDDK NIH HHS R01 DK069921NIDDK NIH HHS T35 DK007383
6 · The paper itself

Abstract

purposeWilms tumor is the most common renal neoplasm of childhood. We previously found that restricted activation of the WNT/β-catenin pathway in renal epithelium late in kidney development is sufficient to induce small primitive neoplasms with features of epithelial Wilms tumor. Metastatic disease progression required simultaneous addition of an activating mutation of the oncogene K-RAS. We sought to define the molecular pathways activated in this process and their relationship to human renal malignancies. MATERIALS AND

methodsAffymetrix® expression microarray data from murine kidneys with activation of K-ras and/or Ctnnb1 (β-catenin) restricted to renal epithelium were analyzed and compared to publicly available expression data on normal and neoplastic human renal tissue. Target genes were verified by immunoblot and immunohistochemistry.

resultsMouse kidney tumors with activation of K-ras and Ctnnb1, and human renal malignancies had similar mRNA expression signatures and were associated with activation of networks centered on β-catenin and TP53. Up-regulation of WNT/β-catenin targets (MYC, Survivin, FOXA2, Axin2 and Cyclin D1) was confirmed by immunoblot. K-RAS/β-catenin murine kidney tumors were more similar to human Wilms tumor than to other renal malignancies and demonstrated activation of a TP53 dependent network of genes, including the transcription factor E2F1. Up-regulation of E2F1 was confirmed in murine and human Wilms tumor samples.

conclusionsSimultaneous activation of K-RAS and β-catenin in embryonic renal epithelium leads to neoplasms similar to human Wilms tumor and associated with activation of TP53 and up-regulation of E2F1. Further studies are warranted to evaluate the role of TP53 and E2F1 in human Wilms tumor.

Indexed as

Disease Models, AnimalAnimalsbeta CateninE2F1 Transcription FactorGene Expression Regulation, NeoplasticGenotypeKidneyKidney NeoplasmsMiceMice, Mutant StrainsOligonucleotide Array Sequence AnalysisProto-Oncogene Proteins p21(ras)Transcriptional ActivationTranscriptomeTumor Suppressor Protein p53Up-Regulationbeta CateninCTNNB1 protein, mouseE2f1 protein, mouseE2F1 Transcription FactorHras protein, mouseProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53animalbeta cateninkidneymodelsoncogenesWilms tumor

Identifiers

PMID25934441
PMCPMC4782590
OpenAlexW2149891163

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.